STA
ISEE

Summit Trail Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Summit Trail Advisors’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-335
Closed -$1K – 1797
2017
Q4 		$1K Buy
+335
New +$942 ﹤0.01% 1904

Other funds holding ISEE

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Trail Advisors's ISEE Position: Q1 2018 in Review

Summit Trail Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q1 2018, closing a stake of 335 shares — an estimated $1K sold.

Summit Trail Advisors first reported a position in ISEE in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 71 funds tracked by Wall St. Rank hold ISEE as of Q1 2018.

  • Summit Trail Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 335 IVERIC bio, Inc. Common Stock shares in Q1 2018, an estimated $1K.
  • Summit Trail Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's IVERIC bio, Inc. Common Stock position peaked at $1K in Q4 2017.
  • 71 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.